NCT06249048
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 49 words Show 6 more changesShow less
- Primary endpoints: details revised at 1 of 2 entries
- Trial completed
- Final enrollment: 39 participants (planned 108)
- Primary completion date changed from estimate of May 2027 to Jun 17, 2026
- Secondary endpoints: details revised at 3 of 9 entries
- Site details revised at 7 of 7 sites
- Notable Eligibility criteria revised
- Study sites: 4 to 7
- Study description expanded, about 37 words
- Study arms: 3 to 5
- Minor Secondary endpoints: 8 to 9v7
- Notable Eligibility criteria shortened, about 1 wordv6
Notable Eligibility criteria expanded, about 141 wordsv5 Show 4 more changesShow less
- Primary endpoints revised (2)
- Secondary endpoints: 14 to 8
- Study description shortened, about 1 word
- Study title expanded, about 2 words
Show 3 earlier versionsHide 3 earlier versions
- Minor Site details revised at 3 of 4 sitesv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 5 to 4
- Start date changed from estimate of Apr 2024 to May 3, 2024
- Notable Primary endpoints revised (2)
- Secondary endpoints: 9 to 14
- Study title shortened, about 2 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
A Phase 1, first-in-human (FIH), multiple ascending dose administration of intratumoral STX-001 monotherapy to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity in patients with advanced cancers. Consists of four planned dose-escalation cohorts (Cohorts 1m) plus permitted backfill enrollment (up to 30 patients). New patients are enrolled in each dose escalation cohort, and dose escalation may be stopped early if emerging PK or safety data warrant it. Dose extension and treatment pauses are integrated, with a maximum extension of 35 cycles (≈24 months).
A Phase 1, first-in-human (FIH), multiple ascending STX-001 dose administration, in combination with pembrolizumab, to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers. Consists of 4 planned dose escalation cohorts (Cohorts 1c) of STX-001and pembrolizumab given concurrently, with new patients enrolled in each dose escalation cohort. Dose escalation may be halted early if PK or safety data indicate, and the dose extension period extends up to 35 cycles with treatment pauses. Backfill enrollment is permitted up to 30 patients.
Phase 2 consists of dose expansion cohorts in patients with 2 defined cancer types: triple negative breast cancer (TNBC) and melanoma. Phase 2 will evaluate STX-001 in combination with pembrolizumab; the recommended Phase 2 dose (RP2D) of STX-001 will be selected based on analysis of the totality of data from Phase 1 safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy data. Dose extension and treatment pauses are incorporated.
Phase 1, first-in-human (FIH) monotherapy cohort targeting visceral lesions. STX-001 is administered intratumorally at 30 µg, 100 µg and 300 µg to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers. Cohort 1Vm is part of the dose escalation stage; new patients are enrolled at each dose level, and backfill enrollment is permitted up to 30 patients. Dose escalation may be stopped early if PK or safety data warrant it.
Phase 2 dose expansion cohort evaluating STX-001 monotherapy administered intratumorally to patients with advanced melanoma. Assesses safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity with the recommended dose selected based on Phase 1 data. Dose extension and treatment pauses are allowed up to 35 cycles.
Biologicals: STX-001, Keytruda®
Sites
7 sites in 2 countries
United States 6, Australia 1